StockData
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. (COCP) stock

COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$0.98−0.01 (-1.00%)

Close on Nov 13, 2026Market cap $18.88MP/E –Yield –

Cocrystal Pharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Cocrystal Pharma's ebitda for the twelve months ending Jun 30, 2026 was -$10.06M. For fiscal 2025 it was -$8.95M. The highest annual figure on record is $400.52K in fiscal 2010.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.95M–
FY2024Dec 31, 2024-$17.75M–
FY2023Dec 31, 2023-$18.37M–
FY2022Dec 31, 2022-$38.64M–
FY2021Dec 31, 2021-$14.03M–
FY2020Dec 31, 2020-$9.43M–
FY2019Dec 31, 2019-$48.31M–
FY2018Dec 31, 2018-$62.87M–
FY2017Dec 31, 2017-$8.16M–
FY2016Dec 31, 2016-$105.62M–
FY2015Dec 31, 2015-$53.76M–
FY2014Dec 31, 2014-$5.60M–
FY2013Dec 31, 2013-$3.85M–
FY2012Dec 31, 2012-$2.41M–
FY2011Dec 31, 2011-$3.36M-937.7%
FY2010Dec 31, 2010$400.52K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.17M–
Q1 FY2026Mar 31, 2026-$2.34M–
Q4 FY2025Dec 31, 2025-$2.47M–
Q3 FY2025Sep 30, 2025-$2.08M–
Q2 FY2025Jun 30, 2025-$2.09M–
Q1 FY2025Mar 31, 2025-$2.32M–
Q4 FY2024Dec 31, 2024-$3.20M–
Q3 FY2024Sep 30, 2024-$5.01M–
Q2 FY2024Jun 30, 2024-$5.42M–
Q1 FY2024Mar 31, 2024-$4.12M–
Q4 FY2023Dec 31, 2023-$4.63M–
Q3 FY2023Sep 30, 2023-$4.39M–
Q2 FY2023Jun 30, 2023-$4.29M–
Q1 FY2023Mar 31, 2023-$5.06M–
Q4 FY2022Dec 31, 2022-$4.45M–
Q3 FY2022Sep 30, 2022-$5.65M–
Q2 FY2022Jun 30, 2022-$24.38M–
Q1 FY2022Mar 31, 2022-$4.16M–
Q4 FY2021Dec 31, 2021-$3.65M–
Q3 FY2021Sep 30, 2021-$3.91M–
Q2 FY2021Jun 30, 2021-$3.78M–
Q1 FY2021Mar 31, 2021-$2.69M–
Q4 FY2020Dec 31, 2020-$1.42M–
Q3 FY2020Sep 30, 2020-$2.67M–
Q2 FY2020Jun 30, 2020-$3.41M–
Q1 FY2020Mar 31, 2020-$1.93M-166.6%
Q4 FY2019Dec 31, 2019-$47.90M–
Q3 FY2019Sep 30, 2019-$1.78M–
Q2 FY2019Jun 30, 2019-$1.53M–
Q1 FY2019Mar 31, 2019$2.90M–
Q4 FY2018Dec 31, 2018-$56.29M–
Q3 FY2018Sep 30, 2018-$2.41M–
Q2 FY2018Jun 30, 2018-$2.12M–
Q1 FY2018Mar 31, 2018-$2.05M–
Q4 FY2017Dec 31, 2017-$1.81M–
Q3 FY2017Sep 30, 2017-$2.09M–
Q2 FY2017Jun 30, 2017-$2.08M–
Q1 FY2017Mar 31, 2017-$3.10M–
Q4 FY2016Dec 31, 2016-$94.34M–
Q3 FY2016Sep 30, 2016-$1.84M–

More Cocrystal Pharma figures

See a number that looks wrong?